We're excited to announce our Series B financing. This round will support the ongoing clinical development of our lead asset, PARG inhibitor ETX-19477, and further advancement of our pipeline. We're also delighted to welcome Monal Mehta, PhD (Avidity Partners) to our Board of Directors. https://lnkd.in/g8MVU__C
858 Therapeutics
生物技术研究
San Diego，California 1,461 位关注者
Discovering innovative small molecule therapeutics for the treatment of cancer
关于我们
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology. 858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery. Building from our collective experience in the fields of epigenetics, single cell genomics, and innate immunity, 858 scientists are dedicated to the company’s mission to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies. 858 is headquartered in the biotech hub of San Diego, CA, and maintains lab operations in both San Diego and New York City, providing proximity to leading investigators and scientific talent on both coasts of the US.
- 网站
-
https://www.8five8tx.com
858 Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Diego，California
- 类型
- 私人持股
- 创立
- 2019
地点
-
主要
获取路线
3115 Merryfield Row
US，California，San Diego，92121
858 Therapeutics员工
动态
-
We're excited to announce our Series B financing. This round will support the ongoing clinical development of our lead asset, PARG inhibitor ETX-19477, and further advancement of our pipeline. We're also delighted to welcome Monal Mehta, PhD (Avidity Partners) to our Board of Directors. https://lnkd.in/g8MVU__C
-
-
It was a pleasure to present our preclinical data on PARG inhibitor ETX-19477 at a packed poster session during AACR! We look forward to initiating clinical trials soon. #AACR24
-
-
It was a pleasure to present our preclinical data on PARG inhibitor ETX-19477 at a packed poster session during AACR! We look forward to initiating clinical trials soon. #AACR24
-
-
We're excited to share the preclinical data on our lead asset, PARG inhibitor ETX-19477, at the AACR 2024 Annual Meeting, which is being held in our hometown of San Diego. https://lnkd.in/dJZp7X9W
-
We are excited to announce that Katherine Bell-McGuinn, M.D., Ph.D. has joined 858 Therapeutics as Chief Medical Officer. The addition of Dr. Bell-McGuinn strengthens the 858 Therapeutics leadership team as the company prepares to initiate clinical trials in 2024. https://lnkd.in/gTcqAPbB
858 Therapeutics Expands Leadership Team to Support Transition to the Clinic
businesswire.com